Western University

Scholarship@Western
Electronic Thesis and Dissertation Repository
4-19-2017 12:00 AM

The Influence of Estrogen on Sex Differences in ChemotherapyInduced Nausea and Vomiting (CINV)
Danna L. Zevy, The University of Western Ontario
Supervisor: Dr. Klaus-Peter Ossenkopp, The University of Western Ontario
Joint Supervisor: Dr. Martin Kavaliers, The University of Western Ontario
A thesis submitted in partial fulfillment of the requirements for the Master of Science degree in
Neuroscience
© Danna L. Zevy 2017

Follow this and additional works at: https://ir.lib.uwo.ca/etd
Part of the Behavioral Neurobiology Commons, and the Biological Psychology Commons

Recommended Citation
Zevy, Danna L., "The Influence of Estrogen on Sex Differences in Chemotherapy-Induced Nausea and
Vomiting (CINV)" (2017). Electronic Thesis and Dissertation Repository. 4538.
https://ir.lib.uwo.ca/etd/4538

This Dissertation/Thesis is brought to you for free and open access by Scholarship@Western. It has been accepted
for inclusion in Electronic Thesis and Dissertation Repository by an authorized administrator of
Scholarship@Western. For more information, please contact wlswadmin@uwo.ca.

Abstract
Chemotherapy-induced nausea and vomiting (CINV) is one of the most distressing events
that affects the quality of life of cancer patients. Evidence suggests that females are more
susceptible to CINV than males, but the mechanism remains unknown. The current thesis
examined whether higher levels of circulating estrogens in females contributes to this sex
difference. CINV was analyzed in a pediatric oncology population, where it was revealed
female patients demonstrate increased delayed CINV relative to male patients, in the postpubertal age group. CINV was also studied by examining the influence of the estrous cycle
on anticipatory nausea (AN) in rats. This study showed that rats in proestrus demonstrate
increased AN relative to rats in diestrus. These results imply that females’ greater likelihood
to experience CINV may be partly due to their higher levels of circulating estrogens.
Uncovering this mechanism will ultimately help to alleviate the burden of CINV on cancer
patients.
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Chapter 1
1 General introduction
The prevalence, course, and severity of many medical and behavioural conditions differ
between males and females (Manton, 1999; Regitz-Zagrosek & Seeland, 2013). These
sex differences arise from a combination of genetic, hormonal, and social factors that
interact to produce widespread differences in the brain and behaviour of the human
population. Despite knowledge of these sex differences, there is little sex-specific
healthcare; sex and gender are often not taken into account when considering the
prevention, treatment, and management of disease (Regitz-Zagrosek, 2012). Moreover,
many animal studies are carried out with male subjects only, thus largely ignoring crucial
sex differences. It is critical that researchers and clinicians take sex into account, as there
are many questions concerning sex differences that have yet to be answered. Though sex
differences in various diseases and conditions have been discovered, the mechanisms
behind many of these sex differences remain largely unclear. Knowledge of these
mechanisms is essential for the employment of more effective and personalized treatment
strategies for many disorders that differentially affect males and females.
One area that has garnered recent interest is sex differences in the experience of nausea
and nausea-related phenomena (Cloutier, Kavaliers, & Ossenkopp, 2017; Hilarius et al.,
2011; Paillard et al., 2013). In a study identifying risk factors for post-operative nausea
and vomiting (PONV), female sex was identified as the strongest patient-related predictor
(Fujii, 2009; Gan, 2006). Female sex is also a known risk factor for motion sickness
susceptibility (Paillard et al., 2013). Moreover, motion sickness has been shown to
fluctuate throughout the menstrual cycle, in accordance with fluctuating estrogen levels
(Golding, Kadzere, & Gresty, 2005). Women also report different factors which
contribute to chronic migraine compared to men, with one of the more prevalent factors
in women being nausea (Özge & Yalın, 2016). There is also a notable sex difference in
the symptomatology reported during acute coronary syndromes. Females are more likely
than males to report nausea, vomiting, and abdominal pain (Arslanian-Engoren, &
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Engoren, 2010; Shin, Martin, & Suls, 2010). Finally, and critical to the present thesis,
female sex is a known risk factor for chemotherapy-induced nausea and vomiting (CINV)
(Molassiotis, Stamataki, & Kontopantelis, 2013; Sekine, Segawa, Kubota, & Saeki, 2013;
Warr, 2014). Female patients experience CINV at higher frequencies than male patients
in the acute, delayed, and anticipatory phases (Gonella & Di Giulio, 2015). In the delayed
phase specifically, female sex is the only patient-related risk factor (Sekine et al., 2013).
Though the mechanism responsible for the sex difference in nausea-related phenomena
has yet to be discovered, there is some evidence that implicates estrogens. The present
thesis explored the possible influence of estrogens on CINV, and on anticipatory nausea
(AN), which is a specific syndrome related to CINV. Two diverse study methodologies
were used. The first consisted of a post hoc data analysis of pediatric oncology patients,
examining sex differences in CINV in these patients at various developmental stages. The
second study employed an animal model of AN which examined differences in
conditioned disgust behaviours in female rats between two of the four phases of the
estrous cycle.
There is no shortage of research in this area using solely male subjects. Unfortunately,
inferences are often drawn from these studies that are applied to both males and females,
which largely ignores the influence of female physiology and biology. The present thesis
focused on female subjects, and the putative contribution of estrogens to CINV.

1.1 Chemotherapy-induced nausea and vomiting (CINV)
Cancer patients undergoing chemotherapy list nausea and vomiting as among the most
debilitating and distressing treatment-related adverse effects (Aapro, Molassiotis, &
Olver, 2005; Molassiotis, 2005). Chemotherapy-induced nausea and vomiting (CINV) is
associated with significant deterioration of quality of life for these patients, and remains a
severe problem in the oncology community (Feinberg, Gilmore, Haislip, Wentworth, &
Burke, 2010). CINV can be acute (24 hours following chemotherapy administration),
delayed (more than 24 hours after and within 7 days of chemotherapy administration), or
anticipatory (within 24 hours prior to chemotherapy administration).
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For adults undergoing chemotherapy, there are a number of known risk factors associated
with CINV. These include: age below 55 years, female sex, non-habitual alcohol use, and
history of nausea including pregnancy-related morning sickness and motion-sickness
(Molassiotis et al 2013; Sekine et al., 2013; Warr, 2014). Taking these risk factors into
account when selecting CINV prophylaxis for individual patients may improve complete
CINV control rates. Unfortunately, in children, risk factors for the development of CINV
are currently unknown. Although there are several possible risk factors, the present thesis
focused on one potential risk factor in children: female sex. Knowledge of patient-related
risk factors for CINV would permit tailoring of standard CINV prophylaxis to meet the
needs of individual children and would likely result in complete CINV control in a higher
proportion of children. In the present thesis, patients were split into three groups: pre-,
mid-, and post-pubertal, in order to pinpoint exactly when the sex difference in CINV
may arise.
One stage of CINV that is particularly challenging to study is anticipatory CINV.
Anticipatory CINV is the experience of nausea and vomiting in the 24 hours leading up
to chemotherapy administration, in anticipation of the treatment itself. Anticipatory
CINV is difficult to control once it develops, and it does not respond well to
pharmacological or non-pharmacological treatment strategies (Tyc, Mulhern, Barclay,
Smith, & Bieberich, 1997). Currently, the best treatment of anticipatory CINV is to
prevent it from occurring in the first place, by controlling acute and delayed CINV (Chan
et al., 2015). The prevalence of anticipatory CINV reported in the literature ranges from
8%–30% of patients (Molassiotis et al., 2016; Morrow et al., 1998). It is posited that
anticipatory CINV develops through classical conditioning (Bovbjerg, 2006; Stockhorst,
Steingrueber, Enck, & Klosterhalfen, 2006). The chemotherapy acts as the unconditioned
stimulus, which elicits nausea and vomiting, the unconditioned response. The physical
hospital or room acts as the conditioned stimulus and after repeated pairings, these
environmental stimuli alone can elicit nausea and vomiting (Tyc et al., 1997). The
prevalence and severity of anticipatory CINV are the basis for the development of an
animal model (Limebeer et al., 2006; 2008).
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1.2 Animal model
A rat model of anticipatory CINV has been well established and is used as a preclinical
tool to study possible treatments (Limebeer et al., 2006; 2008). This model refers to the
condition as anticipatory nausea (AN; Limebeer et al., 2006; 2008). The AN model uses
the toxin, lithium chloride (LiCl), a nausea-inducing drug, as the unconditioned stimulus,
and a distinctive context as the conditioned stimulus. This paradigm demonstrates rats’
ability to associate toxin-induced nausea with the context in which they experienced it.
Rats are injected with LiCl and placed in a distinctive context immediately after injection.
After numerous pairings, rodents are capable of associating this distinctive context with
“feelings” of nausea. When rodents are re-exposed to the context drug-free, they will
demonstrate a conditioned-gaping response, which is a learned response. This wellestablished animal model is a valuable pre-clinical tool for examining possible risk
factors and treatments for AN (Cloutier et al., 2017; Limebeer et al., 2006; 2008).
Sex differences have been observed in this animal model. On drug-free test day, female
rats demonstrate significantly more conditioned gaping responses than male rats (Cloutier
et al., 2017). This is consistent with other animal studies; sex differences in favour of
females have been seen in the development of motion-sickness in the musk shrew (Javid
& Naylor, 1999), as well as in many clinical studies that point to female sex as a risk
factor for a number of nausea-related phenomena (Arslanian-Engoren, & Engoren, 2010;
Fujii, 2009; Gan, 2006), including CINV (Molassiotis et al., 2013; 2016).

1.3 Estrogens
Although this sex difference is well established, further exploration is necessary to
examine the mechanism underlying this sex difference. It has been suggested that
gonadal hormones, specifically estrogens, play a role in this etiology. Estradiol has been
shown to have some natural illness-inducing properties (Ganesan & Simpkins, 1991;
Goodman & Gilman, 1975). When paired with a novel sucrose taste, estradiol produces a
conditioned taste avoidance and disgust response to the novel taste (Ossenkopp, Rabi, &
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Eckel, 1996). Estradiol can also have an additive effect on the LiCl-induced conditioned
disgust in castrated male rats (Lin, Tsai, Tai, & Yeh, 2015).
Estrogens also have stimulatory effects on the serotonergic system. Acute estradiol
administration to ovariectomized rats increases serotonin levels in a number of brain
regions, including the hippocampus (Johnson & Crowley, 1983). Evidence suggests that a
large number of estrogen receptors are expressed in the dorsal raphe nuclei, where most
serotonin neurons are located (Merchenthaler, Lane, Numan, & Dellovade, 2004).
Consequently, estrogen replacement increases neuronal activity in this this region
(Dalmasso, Amigone, & Vivas, 2011). Serotonin (specifically 5-HT3) antagonism has
well-established anti-emetic effects, thus implicating the serotonergic system in the
production of nausea and vomiting (Hesketh, 2000). Therefore, estrogens may increase
nausea and vomiting through a downstream serotonergic process.
There is some indication of an evolutionary explanation for estrogen’s enhancing effect
on nausea. It has been proposed that nausea and vomiting during pregnancy evolved as an
evolutionarily adaptive mechanism to avoid the ingestion of harmful toxins, thus
potentially harming the fetus (Buss, 1999; Profet, 1995). The vomiting and disgust
reflexes have long been regarded as evolutionarily adaptive, as they protect the individual
from ingesting potentially poisonous or noxious substances. It is possible that estrogen
causes this sense to be particularly heightened in women, who have the added
responsibility of protecting their developing offspring from harm (Sherman & Flaxman,
2002).
Estrogens are a class of hormones that naturally fluctuate through the course of a
woman’s lifetime. Estrogens begin to rise during puberty, fluctuate throughout the
menstrual cycles, and begin to decline after menopause. Thus, it is possible to observe
estrogen’s effects on nausea by examining the course of nausea-related phenomena in
different stages of the lifespan of a woman. Motion sickness has been shown to fluctuate
throughout the menstrual cycle, in accordance with fluctuating estrogen levels (Golding,
Kadzere, & Gresty, 2005). Additionally, motion sickness susceptibility and chronic
migraine demonstrate age-dependent decreases in the experience of nausea in women but
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not men. After menopause, motion sickness susceptibility decreases and nausea no longer
predicts chronic migraine (Özge et al, 2014; Paillard et al., 2013).

1.4

Objectives of the current thesis

The first objective of this thesis was to explore the association between CINV control as
assessed by pediatric oncology patients and/or their parents and the patient-related factors
of sex and pubertal status. The study involved a post hoc analysis using integrated data
from three prospective, observational studies which examined acute, delayed, and
anticipatory CINV in pediatric oncology patients at The Hospital for Sick Children
(SickKids) in Toronto. The study explored sex differences in pre-, mid-, and postpubertal children in order to elucidate the possibility that sex differences in CINV only
arise post pubertally.
The second objective of this thesis was to examine the ability of female rodents to
process and associate a distinctive context with an internal sickness cue (i.e., LiClinduced nausea) in the rodent model of AN, and to test whether estrous cycle phase
influences the formation of AN. Specifically, using a conditioned disgust paradigm,
female rats conditioned and tested during proestrus (high estrogen levels) were compared
to those conditioned and tested during diestrus (low estrogen levels) to determine if
estrogen is modulating the observed sex difference in the literature.
The current study examined sex differences in CINV by considering two very different
subject groups. In Chapter 2, pediatric patients were examined, while in Chapter 3, adult
female rats were the subjects. Much of the sex differences in CINV literature focuses on
adult patients, while the pediatric population has been less investigated. The present study
focused on this less examined patient age group, in order to shed some light on the
possible sex differences that may or may not be present in this population.
Although it has been well established that females are more likely to develop CINV
(including but not limited to the anticipatory phase), further research is necessary to
determine the mechanism contributing to this sex difference. It was hypothesized that
estrogen is the contributing factor to females’ greater propensity to experience CINV than
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their male counterparts. This hypothesis was explored through diverse studies, uniquely
combining human and rodent subjects, whose results will strengthen the estrogen
hypothesis with converging evidence.
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Chapter 2
2

Examining the Association Between Sex, Pubertal
Status, and the Development of Chemotherapy-Induced
Nausea and Vomiting (CINV) in Pediatric Oncology
Patients

2.1 Introduction
Cancer patients undergoing chemotherapy list nausea and vomiting as among the most
debilitating and distressing treatment-related adverse effects (Aapro, Molassiotis, &
Olver, 2005; Molassiotis, 2005). Chemotherapy-induced nausea and vomiting (CINV) is
associated with significant deterioration of quality of life for these patients, and remains a
severe problem in the pediatric oncology community (Feinberg, Gilmore, Haislip,
Wentworth, & Burke, 2010). CINV can be acute (24 hours following chemotherapy
administration), delayed (more than 24 hours after and within 7 days of chemotherapy
administration), or anticipatory (within 24 hours prior to chemotherapy administration).
Despite the routine administration of modern CINV prophylaxis based on the emetic risk
carried by the planned chemotherapy regimen, up to 55% of children receiving
moderately or highly emetogenic chemotherapy experience CINV (Kang et al., 2015,
Kovacs et al., 2016). Chemotherapy-induced nausea (CIN) and chemotherapy-induced
vomiting (CIV) are considered as separate entities and are often analyzed separately.
While modern antiemetics have vastly improved CIV control rates over the past decade,
CIN remains more difficult to measure, as well as to control (Rapoport, Molasiotis,
Raftopoulos, & Roila, 2015).
For adults undergoing chemotherapy, there are a number of known risk factors associated
with CINV. Taking these risk factors into account when selecting CINV prophylaxis for
individual patients may improve complete CINV control rates. These risk factors include:
age (below 55 years), non-habitual alcohol use, past history of nausea including
pregnancy-related morning sickness and motion-sickness, and female sex (Molassiotis,

15
Stamataki, & Kontopantelis, 2013; Sekine, Segawa, Kubota, & Saeki, 2013; Warr, 2014).
Female patients experience CINV at higher frequencies than male patients in both the
acute and delayed phases (Gonella & Di Giulio, 2015). In the delayed phase specifically,
female sex is the only patient-related risk factor (Sekine et al., 2013). Although clinicians
are aware of this, the mechanism by which this sex difference operates remains unclear.
Sex differences in favour of females have also been seen in post-operative nausea and
vomiting as well as susceptibility to motion sickness (Fujii, 2009; Paillard et al., 2013).
It has been suggested that sex hormones, specifically estrogens, may play a role in CINV.
Several animal studies have shown that estrogens enhance conditioned aversion
behaviour and may increase nausea and malaise (Fudge, Kavaliers, Baird, & Ossenkopp,
2009; Ganesan, 1994). Estradiol itself has been found to produce both conditioned taste
avoidance when paired with a novel sucrose taste, as well as a strong shift in palatability
of the sucrose taste (Ossenkopp, Rabi, & Eckel, 1996). This may occur because of
estradiol’s illness-inducing properties, which has been seen in animal studies (Ganesan &
Simpkins, 1991) as well as in humans (Goodman & Gilman, 1975).
Although investigators have observed signals that CINV is more problematic in adult
females compared to adult males, a sex difference in pediatric populations is less evident
(Freedman et al., 2014). As of now, chemotherapy emetogenicity is the strongest known
determinant of CINV in children. While recent pediatric CINV studies have not found
female sex to be a significant predictor, these studies have not taken pubertal status into
consideration when examining sex differences (Aseeri, Mukhtar, Khansa, Elimam, &
Jastaniah, 2013; Dupuis et al., 2017; Holdsworth, Raisch & Frost, 2006; Vol et al., 2016).
If in fact gonadal hormones such as estrogens contribute to the sex difference in adults, it
is possible that a sex difference has not been seen in the pediatric population due to the
relatively low levels of circulating gonadal hormones in children. The present study
specifically differentiated pubertal status to examine the possibility that sex differences in
CINV only arise post puberty. It was hypothesized that sex differences would only appear
in patients in the post pubescent group.
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The present study involved a post hoc analysis using integrated data from three
prospective, observational studies which examined acute, delayed, and anticipatory CINV
in pediatric oncology patients at The Hospital for Sick Children (SickKids) in Toronto.
The primary objective of this study was to explore the association between CINV control
as assessed by patients and/or their parents and the patient-related factors of sex and
pubertal status. Any sex differences found (or lack thereof) may then be used by
clinicians to personalize CINV prophylaxis provided to children receiving chemotherapy.
Finding a post pubertal CINV sex difference would also point to a role for gonadal
hormones in the observed sex difference in CINV seen in adults. Finally, knowledge of
patient-related risk factors for CINV would permit tailoring of standard CINV
prophylaxis to meet the needs of individual children and would likely result in more
complete CINV control in a higher proportion of children.

2.2 Method
Data for the current analysis were pooled from three prospective, observational studies
completed at SickKids. The three studies included in this post hoc analysis are outlined in
Table 2.1. All studies collected information on the prevalence of acute, delayed, and
anticipatory CINV in children receiving chemotherapy. All studies were approved by the
SickKids Research Ethics Board. The following is a brief overview of the study
methodology. For more detailed descriptions, see the methodologies from the original
studies (Flank et al., 2017a; Flank et al., 2017b; Vol et al., 2016).

2.2.1 Patients
Data were collected from 160 patients (105 male and 55 female, ages 4 to 18, M= 9.56
years, SD= 3.90 years). Common eligibility criteria in all three studies were as follows:
patients had to have been English speaking, and have the cognitive ability believed to be
at least at a 4-year-old level according to a parent or health care professional. Informed
consent was obtained from eligible patients aged 16 years or older. For eligible patients
younger than 16 years, informed consent was obtained from the parent or guardian and,
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Table 2.1
Summary of Studies Used in Post Hoc Analysis
Study
a

Chemotherapyinduced nausea and
vomiting in children
receiving ifosfamide
plus etoposide,
dactinomycin plus
vincristine, high dose
methotrexate, or high
dose methotrexate plus
vincristine
b

Prevalence of
chemotherapy-induced
nausea and vomiting in
children receiving
hematopoietic stem cell
transplantation
conditioning (HSCT)

N
(m:f)
36

-

Receiving ifosfamide 1800mg/m2/day plus etoposide
100mg/m2/day, dactinomycin 45µg/kg/dose plus
vincristine 1.5mg/m2/dose, methotrexate >1g/m2,
methotrexate >1g/m2 plus vincristine 1.5mg/m2/dose
or equivalent in cases of dose reduction in response
to renal or hepatic impairment

54

-

(31:23)

-

Receiving HSCT conditioning for their first HSCT
for any indication other than immunodeficiency
HSCT conditioning regimen started at The Hospital
for Sick Children

(23:13)

c

Chemotherapyinduced nausea and
vomiting in children
receiving intrathecal
methotrexate
with/without vincristine

Additional Eligibility Criteria

70
(51:19)
-

Receiving intrathecal methotrexate in the context of
maintenance therapy for acute lymphoblastic
leukemia and as dosed by age per protocol. Patients
also received their protocol driven maintenance
chemotherapy which includes oral 6 mercaptopurine
and may include IV vincristine and an oral steroid
pulse (prednisone or dexamethasone).
Patients were past their first cycle of maintenance
therapy to avoid interactions with the intensive
chemotherapy phase
Not receiving chemotherapy other than dictated by
protocol for maintenance therapy within 24 hours
prior to or 24 hours following receipt of intrathecal
methotrexate

a

Vol, H., Flank, J., Lavoratore, S. R., Nathan, P. C., Taylor, T., Zelunka, E., . . . Lee Dupuis, L. (2016). Poor
chemotherapy-induced nausea and vomiting control in children receiving intermediate or high dose
methotrexate. Supportive Care in Cancer, 24(3), 1365-1371.
b

Flank, J., Sparavalo, J., Vol, H., Hagen, L., Stuhler, R., Chong, D,, Courtney, S., Doyle, J. J., Gassas, A., Schechter,
T., Dupuis, L. L. (2017b). The burden of chemotherapy-induced nausea and vomiting in children receiving
hematopoietic stem cell transplantation conditioning: a prospective study. submitted for publication
c

Flank, J., Nadeem, K., Moledina, S., Khanna, M., Schindera, C., Punnett, A. S., Dupuis, L. L. (2017a). Nausea and
vomiting in children and adolescents receiving intrathecal methotrexate: a prospective, observational study. submitted
for publication
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in the case of children aged 7-15 years, assent was obtained from the child as well. See
Table 2.1 for additional eligibility criteria for each study.

2.2.1.1

Pubertal status designation

Pubertal status of each participant was defined using sex-specific age cut-offs, based on
norms for precocious and late onset puberty in the literature (Carel, Lahlou, Roger, &
Chaussain, 2004; Sedlmeyer & Palmart, 2002). Males between the ages of 1 to 9 years
were defined as “pre-pubertal”, between 9.1 to 14 years as “mid-pubertal”, and between
14.1 to 18 years as “post-pubertal”. Females between the ages of 1 to 8 years were
defined as “pre-pubertal”, between 8.1 to 13 years as “mid-pubertal”, and between 13.1
to 18 years as “post-pubertal”. See Table 2.2 for sample size of each of these pubertal
groups.

2.2.2 Data collection
Structured diaries were used to collect CINV data. A validated nausea assessment
instrument, the pediatric nausea assessment tool (PeNAT; Dupuis, Taddio, Kerr, Kelly, &
MacKeigan, 2006), was used to measure nausea. The PeNAT, which has been validated
for children aged 4 to 18 years, incorporates a facial expression scale with a standard
script. Through the use of the facial scale and script, children can focus on the expression
being asked of them and select the facial expression that best describes their feelings.
Nausea is then translated onto a Likert scale from 1 to 4 (1 being no nausea to 4 being
worst nausea) (Dupuis et al., 2006). Emetic episodes as well as antiemetic administration
were also recorded in the diaries. Vomiting was defined as the expulsion of any stomach
contents by the mouth. Retching was defined as an attempt to vomit that is not productive
of any stomach contents. An emetic episode was defined as a vomit or retch separated
from another vomit or retch by at least 1 minute. A study investigator explained study
procedures to each patient and/or parent or guardian and administered the PeNAT to the
child at least once in the presence of the parent or guardian. The number of emetic
episodes recorded by the child/parent/guardian was compared against the nursing flow
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Table 2.2
Sample Size By Pubertal Status and Sex

Pre Pubertal

Mid Pubertal

Post Pubertal

Totals

Males

52

43

10

105

Females

26

13

16

55
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sheets for inpatients, and in the case of discrepancy, the higher number was used. All
diary pages completed during the inpatient period were collected prior to discharge. The
diary pages completed during the outpatient period were returned to the investigator via
mail or in person at a subsequent hospital visit.

2.2.3 Outcomes
2.2.3.1

Anticipatory CINV

Anticipatory CINV was defined as nausea, vomiting, or retching in the 24 hours prior to
chemotherapy administration in patients that have received chemotherapy previously.
The child was asked if he/she felt nauseated or vomited in the last 24 hours before his/her
first chemotherapy dose in the study course. The parent(s)/guardian(s) were asked
separately if their child vomited or felt nauseated within the last 24 hours before his/her
first chemotherapy dose in the course to confirm the information provided by the child.
Anticipatory CINV was quantified by presence or absence.

2.2.3.2

Acute and delayed phase CINV

Acute CINV was defined as nausea, vomiting, or retching occurring within 24 hours
following chemotherapy administration. Delayed CINV was defined as nausea, vomiting,
or retching which occurs between 25 hours up to 7 days following chemotherapy
administration. The time that each emetic episode occurred was recorded by the child or
parent in the diary. Children were able to rank nausea as none, mild, moderate, or severe
using the PeNAT. Both acute and delayed CINV were quantified with a score of “level of
control over CINV” (Likert scale of 1-3, 1 being complete control, 2 being partially
controlled, 3 being uncontrolled). The primary study endpoint was complete control of
CINV which was defined as no nausea (maximum PeNAT score of 1) and no emetic
episodes. Partial CINV control was defined as a maximum PeNAT score of 2 during the
phase of interest, or 1 or 2 emetic episodes in any 24-hour period. Uncontrolled CINV was
defined as a maximum PeNAT score of 3 or 4 during the phase of interest, or more than 2
emetic episodes in any 24-hour period.
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2.2.4 Data analysis
Dependent variables quantified were the proportion of participants that developed
anticipatory CIN, CIV, and CINV, the overall level of control of acute CIN, CIV, and
CINV, and the overall level of control of delayed CIN, CIV, and CINV. Independent
variables examined were sex (male and female) and pubertal status (pre-pubertal, midpubertal, and post-pubertal). All statistical tests used α=0.05 as a significance criterion.
Statistical analysis were performed using IBM SPSS Statistics 23 for Windows.

2.2.4.1

Anticipatory CINV

Data was analyzed using three separate chi-square tests to explore the association
between sex and proportion of patients who develop anticipatory CIN, CIV, and CINV,
for each of the three pubertal groups of interest.

2.2.4.2

Acute and delayed phase CINV

Data was analyzed using 2 X 3 between subjects analysis of variances (ANOVA) with
two between subject factors of Sex (at two levels: male and female) and Pubertal Status
(at three levels: pre-pubertal, mid-pubertal, and post-pubertal) for CIN, CIV, and CINV
each separately. This analysis compared mean CINV control scores (higher indicating
increased CINV) for each of the groups of interest. A priori planned comparisons were
performed on each pubertal group separately, as this was the specific focus of the study.
This was done using three separate one-way ANOVAs on each pubertal group, with one
between subject factor of sex (at two levels: male and female).
The number of individuals experiencing either completely controlled, partially controlled,
or uncontrolled CINV were also calculated as a proportion of total in each group of
interest (pre-pubertal males, pre-pubertal females, mid-pubertal males, mid-pubertal
females, post-pubertal males, and post-pubertal females). This was done separately for
anticipatory, acute, and delayed CINV. Subsequently, chi square analyses were
performed to compare these frequencies, to further ascertain if sex differences exist in
level of control of CINV in each pubertal group.
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2.3 Results
2.3.1 Anticipatory CIN, CIV, and CINV
Three separate chi-square analyses revealed no significant differences between males and
females for any of the pubertal groups. The proportion of children experiencing
anticipatory CINV in each of the pubertal groups is shown in Table 2.3. For all pubertal
groups, no relationship was found between sex and development of CIN, CIV, or CINV.

2.3.2 Acute CIN, CIV, and CINV control
The proportion of children who experienced complete, partial, or no control of CIN, CIV,
and CINV in the acute phase is summarized in Table 2.4. The 2 X 3 between-subjects
ANOVA revealed no significant Sex or Pubertal Status effects for acute CIN, CIV, or
CINV. Since pubertal status was of particular interest in this study, a priori planned
comparisons were done in order to explore possible Sex effects in each of the pubertal
status groups. The one-way ANOVA revealed no significant Sex effect in any of the
pubertal status groups. The chi square analyses also revealed no significant differences in
any of pubertal groups for acute CIN, CIV, and CINV control.

2.3.3 Delayed CIN, CIV, and CINV control
The proportion of children who experienced complete, partial, or no control of CIN, CIV,
and CINV in the delayed phase is summarized in Table 2.5. For CIV, the 2 X 3 between
subjects ANOVA revealed a significant main effect of Sex, F(1,154)= 7.76, p < .01. For
CIN and CINV, the 2 X 3 between-subjects ANOVA revealed no significant Sex or
Pubertal Status effects. Since pubertal status was of particular interest in this study, a
priori planned comparisons were done in order to explore possible Sex effects in each of
the pubertal status groups. For both CIN and CINV, the one-way ANOVA revealed a
significant main effect of Sex in the post pubertal group, F(1,24)= 5.01, p < .05. As
shown in Figure 2.1, post pubertal females demonstrated a significantly higher mean
“level of control of delayed CINV” score, which translates to higher levels of
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Table 2.3
Prevalence of Anticipatory CINV by Sex and Pubertal Status
Number of patients experiencing anticipatory chemotherapy-induced
nausea and vomiting (%)
CINV

CIV

CIN

Pre Pubertal

Male
8 (15)

Female
5 (19)

Male
4 (8)

Female
2 (8)

Male
8 (15)

Female
5 (19)

Mid Pubertal

9 (21)

2 (15)

5 (12)

2 (15)

7 (16)

2 (15)

Post Pubertal

1 (10)

5 (31)

0 (0)

2 (13)

1 (10)

4 (25)

CINV chemotherapy-induced nausea and vomiting, CIV chemotherapy-induced
vomiting, CIN chemotherapy-induced nausea.
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Table 2.4
Prevalence of Acute CINV by Sex and Pubertal Status
Acute Phase
CINV

CIV

CIN

Male
Number of patients
experiencing
complete controla
(%)
Pre Pubertal 14 (27)

Female

Male

Female

Male

Female

10 (38)

38 (73)

17 (65)

14 (27)

11 (42)

Mid Pubertal 14 (33)

2 (15)

26 (60)

5 (38)

14 (33)

2 (15)

Post Pubertal

1 (10)

3 (19)

7 (70)

9 (56)

1 (20)

3 (19)

Number of patients
experiencing
partial controlb (%)
Pre Pubertal 16 (31)

4 (15)

7 (13)

3 (12)

17 (33)

5 (19)

Mid Pubertal 11 (26)

4 (31)

9 (21)

6 (46)

11 (26)

4 (31)

Post Pubertal

4 (40)

4 (25)

2 (20)

3 (19)

4 (40)

4 (25)

Number of patients
experiencing no
controlc (i.e.
uncontrolled) (%)
Pre Pubertal 22 (42)

12 (46)

7 (13)

6 (23)

21 (40)

10 (38)

Mid Pubertal 18 (42)

7 (54)

8 (19)

2 (15)

18 (42)

7 (54)

Post Pubertal

9 (56)

1 (10)

4 (25)

5 (50)

9 (56)

5 (50)

CINV chemotherapy-induced nausea and vomiting, CIV chemotherapy-induced
vomiting, CIN chemotherapy-induced nausea.
a
Complete control is defined as a max PeNAT score of 1 and/or 0 vomits, retches, or
gags.
b
Partial control is defined as a max PeNAT score of 2 and/or 1-2 vomits, retches, or gags.
c
Uncontrolled is defined as a max PeNAT score of 3-4 and/or > 2 vomits, retches, or
gags.
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Table 2.5
Prevalence of Delayed CINV by Sex and Pubertal Status
Delayed Phase
CINV

CIV

CIN

Male

Female

Male

Female

Male

Female

Number of patients
experiencing
complete control
(%)
Pre Pubertal

18 (35)

8 (31)

39 (75)

12 (46)

18 (35)

9 (35)

Mid Pubertal

15 (35)

5 (38)

24 (56)

6 (46)

15 (35)

5 (38)

Post Pubertal

5 (50)

3 (19)

8 (80)

7 (44)

5 (50)

3 (19)

Number of patients
experiencing partial
control (%)
Pre Pubertal

5 (10)

5 (19)

7 (13)

11 (42)

5 (10)

4 (15)

Mid Pubertal

5 (12)

3 (23)

15 (35)

2 (15)

5 (12)

3 (23)

Post Pubertal

3 (30)

3 (19)

1 (10)

6 (38)

3 (30)

3 (19)

Number of patients
experiencing no
control (i.e.
uncontrolled) (%)
Pre Pubertal

29 (56)

13 (50)

6 (12)

3 (12)

29 (56)

13 (50)

Mid Pubertal

23 (53)

5 (38)

4 (9)

5 (38)

23 (53)

5 (38)

Post Pubertal

2 (20)

10 (63)

1 (10)

3 (19)

2 (20)

10 (63)

CINV chemotherapy-induced nausea and vomiting, CIV chemotherapy-induced
vomiting, CIN chemotherapy-induced nausea.
a
Complete control is defined as a max PeNAT score of 1 and/or 0 vomits, retches, or
gags.
b
Partial control is defined as a max PeNAT score of 2 and/or 1-2 vomits, retches, or gags.
c
Uncontrolled is defined as a max PeNAT score of 3-4 and/or > 2 vomits, retches, or
gags.
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Level of Delayed CINV Control
3

*

Female

2.5
Level of Control (out of 3)

Male

2

1.5

1

0.5

0
Pre Pubertal

Mid Pubertal
Pubertal Status

Post Pubertal

Figure 2.1. Level of Delayed CINV Control. Mean (+ sem) delayed CINV scores (out
of 3, 1= complete control, 2= partial control, 3=uncontrolled) for pre, mid and post
pubertal male and female participants who developed delayed CINV. In the post pubertal
group only, there was a significant sex difference; post pubertal females had less control
of delayed nausea (i.e. experienced more nausea) than post pubertal males *p < .05.
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uncontrolled delayed CINV. No main effect of Sex was seen in any of the other pubertal
groups. The chi square analysis also revealed an association between sex and proportion
experiencing uncontrolled CIN and CINV, for the post pubertal group, X2 (1, N = 26) =
4.301, p < .05. As shown in Figure 2.2, Post pubertal females demonstrated significantly
higher proportions of uncontrolled CIN and CINV compared to post pubertal males. All
other chi square analyses revealed no significant associations.

2.4 Discussion
The present study examined putative sex differences in the development of anticipatory,
acute, and delayed CINV in pediatric oncology patients. Patients were split into three
groups based on pubertal status: pre-, mid-, and post-pubertal. It was hypothesized that
sex differences in the development of CINV would only be seen in the post-pubertal age
group. This post-pubertal sex difference was in fact observed in delayed CINV.
Notably, in both the pre-, and mid-pubertal patients, no sex differences were seen in acute
or delayed CINV control. This agrees with multiple studies which found that female sex
is not a significant predictor of CINV in pediatric oncology patients (Aseeri et al., 2013;
Dupuis et al., 2017; Holdsworth, Raisch & Frost, 2006; Vol et al., 2016). On the other
hand, female sex is a well-established risk factor for CINV in adults (Hesketh, 2008;
Sekine et al., 2013). This seemingly age-dependent sex difference points to some process
occurring in females during adolescence, making them more susceptible to developing
CINV. The results from the present study suggest that this said process may in fact be
puberty. Puberty begins in females when gonadotropin-releasing hormone (GnRH) is
secreted by the hypothalamus, which signals the release of luteinizing hormone (LH) and
follicle-stimulating hormone (FSH). This triggers ovarian production of estrogens, which
are responsible for the behavioral and physiological changes that accompany puberty
(Dietrich, 2014). Serum estradiol levels are significantly higher in post pubertal girls than
post pubertal boys, as well as pre-pubertal children of both sexes (Courant et al., 2010).
This marked rise in estradiol, beginning during puberty, fluctuating throughout the
menstrual cycle, and lasting until menopause, may be connected to the increase in
nausea-related phenomena seen in females. In a study identifying risk factors for post-
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Patients with Uncontrolled Delayed CINV
Male

Children Experiencing No Control(%)

100
90

Female

80
70

*

*

60
50
40
30
20
10
0
Pre

Mid
CIN

Post

Pre

Mid

Post

Pre

CIV

Mid

Post

CINV

Pubertal Status and CINV Phase
Figure 2.2. Uncontrolled Delayed CINV. Proportions of children experiencing
uncontrolled CIN, CIV, and CINV in the delayed phase, grouped by sex and pubertal
status. Post pubertal females demonstrated significantly higher proportions of
uncontrolled delayed CIN and CINV than post pubertal males,* p < .05.
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operative nausea and vomiting (PONV), female sex was identified as the strongest
patient-related predictor (Fujii, 2009; Gan, 2006). Female sex is also a known risk factor
for motion sickness susceptibility (Paillard et al., 2013). Moreover, motion sickness has
been shown to fluctuate throughout the menstrual cycle, in accordance with fluctuating
estrogen levels (Golding, Kadzere, & Gresty, 2005). Women also report different factors
than men which contribute to chronic migraine, one of the more prevalent factors being
nausea (Özge et al, 2014).
Motion sickness susceptibility and chronic migraine demonstrate additional agedependent decreases in the experience of nausea in women but not men. After age 50 –
60 years, motion sickness susceptibility decreases and nausea no longer predicts chronic
migraine (Özge et al, 2014; Paillard et al., 2013). Interestingly, this age range
corresponds to menopause, a time period associated with fluctuations in hormone
concentrations, particularly the gradual decline of estrogens, which may influence nausea
responses in women.
Taken together, the lack of a sex difference in CINV in children, the emergence of a sex
difference in post-pubertal patients in the present study, a well-established sex difference
in the adult population, and finally, the menstrual cycle and menopause related changes
in other nausea related phenomena, all point to some gonadal hormone process operating,
likely estrogens.
The finding of a post-pubertal sex difference in delayed CINV in the present study
provides some evidence that pubertal hormones contribute to the overall sex difference
seen in the adult population. Though no post-pubertal sex differences were found in
anticipatory CINV in the present study, we observed a signal that there may be an
increased chance of anticipatory CINV in post-pubertal females. The lack of significance
may be due to the particularly small sample size in this group. Notably, the most
commonly diagnosed cancer in children is leukemia, which is most prevalent in children
one to four years of age (Greenberg et al., 2015; Canadian Cancer Society, 2016). As
such, the sample size for the post-pubertal age group was the smallest, and should be reexamined with a larger sample size in future studies.
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Some limitations of the present analysis should be mentioned. This is a post hoc analysis
of data, as such these conclusions can only be considered as hypothesis generation. It is
also worth discussing the uneven sample sizes in the present study. Due to the large
proportion of leukemia patients, which is seen predominantly in young children, the
sample sizes in each pubertal group are substantially varied, with the post pubertal groups
being the smallest (10 males and 16 females). Further, the original studies were not
primarily designed to investigate sex differences within each pubertal group. Therefore,
cut-offs for each pubertal group could only be determined retrospectively, using
established norms for precocious and late-onset puberty. Future studies should examine
this research question with a focus on puberty so that clinician-defined pubertal status
determination is part of the study’s methodology, as well as with larger and more evenly
divided sample sizes. Limitations of the original studies include their observational nature
as well as the possibility of selection bias. It is possible that patients who experienced
more severe CINV were more likely to participate in the studies. Additionally, the studies
are limited by the subjective nature of self-report by patients or their parents. However,
the PeNAT has been validated and has shown to be a reliable and accurate indicator of
nausea in pediatric patients (Dupuis et al., 2006).

2.4.1 Conclusions
It was hypothesized that post pubertal female patients would show less CINV control
than post pubertal males, in the anticipatory, acute, and delayed phases. It was found that
post pubertal female patients exhibited significantly less CINV control than post pubertal
male patients. This sex difference was particular to the delayed phase, and was not seen
in the anticipatory or acute phases. The present findings provide support for a post
pubertal CINV sex difference, and provide some indication that gonadal hormones may
be the underlying factor for the observed sex difference in CINV in adults. This study
also indicates female sex as a possible risk factor for CINV in the post-pubertal pediatric
population.
The effects of CINV on individuals experiencing chemotherapy can be debilitating and
extremely discouraging. Although there are a number of known risk factors for
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developing CINV in the adult population, research on risk factors in children up until this
point has been scarce. Developing a comprehensive understanding of the risk factors for
CINV in children will provide a stronger foundation for targeted CINV prophylaxis and,
ultimately, will alleviate some of the stress and discomfort that accompany
chemotherapy.
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Chapter 3
3

The Effect of the Estrous Cycle on the Development of

Anticipatory Nausea (AN) in Female Rats
3.1 Introduction
3.1.1 Anticipatory nausea
Chemotherapy treatment largely contributes to survival rates in cancer patients, due to its
cytotoxic and antineoplastic effects. Unfortunately, chemotherapy also has several
undesirable side effects, including nausea and vomiting. Chemotherapy-induced nausea
and vomiting (CINV) are reported as among the most debilitating and distressing
treatment-related effects (Aapro, Molassiotis, & Olver, 2005; Molassiotis, 2005). As a
result, many patients develop anticipatory CINV whereby they are conditioned to
experience nausea and vomiting in anticipation of the chemotherapy administration. The
prevalence of anticipatory CINV reported in the literature ranges from 8%–30% of
patients (Molassiotis et al., 2016; Morrow et al., 1998). It is posited that anticipatory
CINV develops through classical conditioning (Bovbjerg, 2006; Stockhorst,
Steingrueber, Enck, & Klosterhalfen, 2006). The chemotherapy acts as the unconditioned
stimulus, which elicits nausea and vomiting, the unconditioned response. The physical
hospital or room acts as the conditioned stimulus and after repeated pairings, these
environmental stimuli alone can elicit nausea and vomiting (Tyc, Mulhern, Barclay,
Smith, & Bieberich, 1997). The prevalence and severity of this problem are the basis for
the development of an animal model of anticipatory CINV (Limebeer, et al., 2006; 2008;
Rodriguez, Lopez, Symonds, & Hall, 2000).

3.1.2 Animal model
A rat model of anticipatory CINV, coined anticipatory nausea (AN) for the purpose of
this model, has been well established and is used as a preclinical tool to study possible
treatments (Limebeer et al., 2006; 2008). The model uses the toxin lithium chloride
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(LiCl), a nausea-inducing drug as the unconditioned stimulus, and a distinctive context as
the conditioned stimulus. This paradigm demonstrates rats’ ability to associate toxininduced nausea with the context in which they experienced it. Rats are injected with LiCl
and placed in a distinctive context immediately after injection. On the test day, rats are
placed in the distinctive context drug free, and observed for the disgust behaviours of
gaping, chin rubbing, paw treading, and forelimb flails. Rats are non-emetic species, so
gaping has been well established as a reliable and selective indicator of nausea in rats
(Parker & Limebeer, 2006). Gaping is seen when rats are exposed to drugs known to
have emetic properties, i.e, cause vomiting in species that have this reflex (Parker &
Limebeer, 2006; Travers and Norgren, 1983). A number of studies have shown that a
distinctive context comes to elicit gaping responses in rats after it is paired with injections
of LiCl (Cloutier, Cross-Mellor, Kavaliers, & Ossenkopp, 2011; Limebeer et al., 2006;
2008; Rodriguez et al., 2000). Disgust behaviours are also elicited by aversive tastes such
as bitter quinine (Grill & Berridge, 1985; Grill & Norgren, 1978). This well-established
animal model is a valuable pre-clinical tool for examining possible risk factors and
treatments for AN.

3.1.3 Sex differences and estrogens
Female sex is a known risk factor for AN in adult cancer patients undergoing
chemotherapy. Women are significantly more likely to develop symptoms and less likely
to achieve control (Fetting et al., 1983; Hilarius et al., 2012; LeBaron, Zeltzer, LeBaron,
Scott, & Zeltzer, 1988). Women under the age of 50 are at particular risk for developing
AN. Animal studies, using the rat model of AN, have demonstrated this sex difference as
well. Female rats demonstrated significantly more conditioned gaping behaviour than
male rats at three different doses of LiCl (64, 96, or 128 mg/kg) (Cloutier, Kavaliers, &
Ossenkopp, 2017).
Although this sex difference is well established, further exploration is necessary to
examine the mechanism(s) underlying this difference. It has been suggested that gonadal
hormones, specifically estrogens, play a role in this etiology. Estrogens may be
implicated in the formation of conditioned disgust through the attenuation of conditioned
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learning, or by facilitating nausea itself. Estradiol has been found to produce both
conditioned taste avoidance when paired with a novel sucrose taste, as well as
conditioned disgust responses to the sucrose taste (Ossenkopp, Rabi, & Eckel, 1996).
Estradiol has also been shown to enhance the acquisition of LiCl-induced conditioned
taste aversion (CTA) in castrated male rats (Lin, Tsai, Tai, & Yeh, 2015). This may
occur because of estradiol’s illness-inducing properties, which have been seen in humans
(Goodman & Gilman, 1975) as well as animal studies (Ganesan & Simpkins, 1991).
Estrogens also have stimulatory effects on the serotonergic system. Acute estradiol
administration to ovariectomized rats increases serotonin levels in a number of brain
regions, including the hippocampus (Johnson & Crowley, 1983). Serotonin (specifically
5-HT3) antagonism has well-established anti-emetic effects, thus implicating the
serotonergic system in the production of nausea and vomiting (Hesketh, 2000).
Therefore, estrogens may increase nausea and vomiting through a downstream
serotonergic process.
Interestingly, estrogens—and consequently—serotonin, have stimulatory effects on
hippocampal neurogenesis (Mahmoud, Wainwright, & Galea, 2016). There is no shortage
of research on the involvement of the hippocampus in learning and memory (Josselyn,
Kohler, & Frankland, 2015; Rosenbaum, Winocur, & Moscovitch, 2001; Winocur,
Moscovitch, & Sekeres, 2013). While not the sole structure responsible for memory, the
hippocampus has strong connections to spatial memory (Moser, Rowland, & Moser,
2015). Circulating estrogen levels are positively correlated with cell proliferation and
hippocampal neurogenesis in the female rat. Adult female rats have significantly more
newly proliferating cells in the dentate gyrus during proestrus in comparison to diestrus
(Pawluski, Brummelte, Barha, Crozier, & Galea, 2009). Recent evidence has suggested
that this estrogenic effect on the hippocampus may be mediated by serotonin (Mahmoud,
Wainwright, & Galea, 2016). Thus, connecting estrogens to serotonin, which may have
some involvement in enhancing both nausea and vomiting, and learning and memory,
through different pathways.
There is some evidence that suggests estrogens are involved in learning and memory
through a rapid mechanism that is controlled by intracellular signaling (Frick et al.,
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2004). These effects have been seen in rodents specifically when estradiol is administered
shortly after the acquisition phase of a learning task, implicating the early phase of
memory formation. Additionally, these results have been extended to human research;
estradiol levels are positively correlated to working memory performance in women of
reproductive age (Hampson & Morley, 2013).
Studies have also shown that estradiol improves memory by potentiating glutamatergic
and cholinergic activity. Administration of both 17 β-estradiol and estrone into the
hippocampus of female ovariectomized mice improved retention of T-maze footshock
avoidance (Farr, Banks & Morley, 2000). As well, normally subthreshold levels of
estradiol become effective at improving memory retention when co-administered with
either cholinergic or glutamatergic agnoists. (Farr, Banks, & Morley, 2000). Estradiol
treatment in ovariectomized female rats also leads to increased hippocampal dendritic
spine densities, further supporting the link between estrogens and memory (Woolley &
McEwen, 1993).

3.1.4 Estrous cycle
The reproductive cycle of female rats is known as the estrous cycle. The typical rat
estrous cycle lasts four days and consists of estrus, metestrus, diestrus, and proestrus
(Long & Evans, 1922). Estrogen reaches peak levels at proestrus, while diestrus consists
of baseline estrogen levels. The estrous cycle can be tracked by collecting samples of
vaginal secretion and examining cell type and quantity in these samples. Thus, the effects
of estrogens on various behaviours can be determined by tracking the rats’ estrous cycle,
and quantifying behaviours on specific days of the cycle. Rats in the current study were
conditioned and tested during proestrus, a period of high estrogen circulation, or diestrus,
a period of low estrogen circulation.

3.1.5 Current study
While sex differences in AN and conditioned disgust have been established in the human
as well as animal population, further research is required to determine how estrogens
modulate this phenomenon. The current study investigated possible explanations as to
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why females are more prone to AN than males. Understanding the mechanisms
underlying the sex difference in AN may provide differential prophylactic treatment
strategies to the male and female populations undergoing chemotherapy.
The current study examined the effect of the estrous cycle on the formation of AN in a rat
conditioned disgust model, using an intermediate dose (96 mg/kg) of the nausea-inducing
toxin, LiCl. Based on reported effects of estrogens in the literature, it was hypothesized
that rats in proestrus (i.e. high estrogen levels) would demonstrate stronger conditioned
nausea responses than rats in diestrus (i.e. low estrogen levels).

3.2 Method
3.2.1 Animals
Subjects were 31 naïve female Long-Evans rats (Charles River, Quebec, Canada)
weighing between 125-150g at the start of the experiment. Rats were pair-housed in
standard polypropylene cages (45 cm x 22 cm x 20 cm) in a temperature-controlled
colony room (20 ± 1°C) maintained on a 12:12-h light-dark cycle with lights on from
07:00 to 19:00 h. All testing took place during the light portion of the light-dark cycle.
Rats had ad libitum access to ProLab Rat Chow RMH 3000 and water, except while in
the testing apparatus. All procedures used were carried out in compliance with the
Canadian Council of Animal Care and approved by the Institutional Animal Care
Committee of Western University.

3.2.2 Drugs
Rats (n=15-16/group) were injected intraperitoneally with 96 mg/kg 0.15M LiCl, or 10
ml/kg 0.9% NaCl. All conditioning and testing took place immediately after drug
administration. Doses were based on those employed in previous studies examining the
effect of the drug (Cloutier et al., 2017; Ossenkopp, Biagi, Cloutier, Kavaliers, & CrossMellor, 2011).
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3.2.3 Materials and apparatus
The context-conditioning apparatus was an opaque Plexiglas chamber (22.5 cm x 26 cm x
20 cm) with a gray lid that rested on a transparent glass plate. Below the chamber, a
mirror was mounted at a 45° angle to allow for viewing of the ventral surface of the rats.
Rats were tested in a darkened room with two 40W red lights placed below the glass plate
(see Figure 3.1). This lighting set up was to ensure testing environment was distinctive.
Behavioral responses during the conditioning days and test day were videotaped with a
video camera (Sony DCR-DVD201; London, Ontario) located 1 m from the mirror.

3.2.4 Estrous cycle determination
Reference images for determination of estrous cycle phase can be seen in Figure 3.2. Rats
were acclimatized to their home cages for one week and then handled on three separate
occasions. Following handling, the estrous cycle was tracked daily at the same time each
day for approximately 14 days. The estrous cycles were tracked by the vaginal smear
technique. This involved sampling the cells of the vaginal canal with sterile saline using a
pipette. The recovered solution (approximately 20 µl) containing cells was then placed on
microscope slides for later determination of estrous cycle phase. This was done using a
phase-contrast microscope with 10X magnification. Proestrus was determined by
scattered distribution of predominantly cornified cells and the presence of nucleated cells.
Diestrus was identified by the reduction in the number of cells and the presence of
leukocytes (Marcondes, Bianchi, & Tanno, 2002). Vaginal smears were obtained on a
daily basis for a period of three full estrus cycles prior to testing, after which rats were
divided in proestrus or diestrus groups. All rats used in this study exhibited a regular 4day cycle.

3.2.5 Experimental procedure
The experimental procedure is summarized in Figure 3.3. The experiment consisted of
two phases: a conditioning phase consisting of four days spaced 96 hours apart, and a
drug-free test day, 96 hours following the final conditioning day. There were four
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Figure 3.1. Distinctive Context. On conditioning days, rats are injected with either 96
mg/kg LiCl or 0.9% NaCl and immediately placed in this distinctive context for 30
minutes. On test day, rats are placed in this distinctive context drug-free.

Figure 3.2. Estrous Cycle Phases. Sample slides for each estrous cycle phase.
Metestrus consists of approximately equal proportions of cell types, many leukocytes,
some cornified cells, and some nucleated cells. Diestrus consists of many small
leukocytes, which often branch near edges of slides. Proestrus consists of large clumps
of round, nucleated cells. Estrus consists of sheets of cornified cells and few to no
nuclei. Phases of interest for this study (Proestrus and Diestrus) are shown in boxes.
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Conditioning Days (1, 5, 9, 13)
• Injected intraperitoneally with either 96 mg/kg LiCl or 0.9%
NaCl
• Immediately placed in distinctive context for 30 min
Day: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
Test Day (17)
• Placed into context drugfree for 10 min

Figure 3.3. Experimental Procedure. On each conditioning day, rats are injected with
96 mg/kg LiCl or 0.9% NaCl and immediately placed in the distinctive context.
Conditioning days are spaced 96 hours apart to ensure rats are consistently conditioned
during the phase of each rats’ respective group (proestrus or diestrus). Test day occurs 96
hours following the final conditioning day, where rats are placed into the distinctive
context drug-free.
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experimental groups (n= 7-8/group). Half of the rats were conditioned and tested during
diestrus, and the other half during proestrus. Of those two groups, half were given
intraperitoneal injections of 96 mg/kg 0.15 M LiCl, and half were given control injections
of 0.9% 10 ml/kg NaCl. As shown in Figure 3.4, the four experimental groups were:
Proestrus+LiCl, Proestrus+NaCl, Diestrus+LiCl, and Diestrus+NaCl.

3.2.4.1

Conditioning phase

On each of the four conditioning days (spaced 96 h apart), animals were injected
intraperitoneally with NaCl (0.9%, 10 ml/kg), or LiCl (0.15 M; 96 mg/kg) depending on
experimental group. Immediately following drug administration, each animal was placed
in the distinctive context for 30 minutes. Behaviors were recorded for later scoring using
the Observer (Noldus Information Technology, Sterling, VA) Event-Recording Program.
Dependent behavioural variables analyzed consisted of gaping frequency and other
aversive responses (forelimb flails, paw treads, and chin rubs). Following each exposure
to the distinctive context, a vaginal smear was obtained from each animal to confirm
stage of estrous cycle, and the rat was then returned to its home cage.

3.2.4.2

Drug-free test day

Ninety-six hours following the final conditioning day, each rat was re-exposed to the
distinctive context for 10 min on a drug-free test day. Behaviors were video recorded for
later scoring using the Observer (Noldus Information Technology, Sterling, VA) EventRecording Program. Dependent behavioural variables analyzed consisted of gaping
frequency and the other aversive responses (forelimb flails, paw treads, and chin rubs).
Immediately following 10-minute exposure to distinctive context, a vaginal smear was
again obtained to confirm stage of estrous cycle.

3.2.5 Data analysis
On the four 30 minute conditioning days and on the 10 minute drug-free Test Day,
dependent variables included conditioned gaping behaviour, and other aversion-related

47

31 Females
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8 with
96
mg/kg
LiCl

8 with
0.9%
NaCl

Figure 3.4. Group Designation.

15 Diestrus

7 with
96
mg/kg
LiCl

8 with
0.9%
NaCl
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behaviours, such as, forelimb flails, paw treading, and chin rubs, and finally, a composite
score of these aversion-related behaviours (excluding gaping) (Ossenkopp & Mazmanian,
1985). Gaping was defined as lowering of the jawbone, opening of the mouth, and the
protrusion of the lower teeth (Limebeer et al., 2006; 2008).
Data from conditioning days and test day were analyzed separately. Conditioned gaping
responses and aversion-related behaviours (excluding gaping) on the conditioning days
were analyzed using separate 2 x 2 x 4 mixed design analysis of variances (ANOVA)
with two between-subject factors of Drug (at two levels: 96 mg/kg LiCl and 0.9% NaCl)
and Estrous Cycle Phase (at two levels: proestrus and diestrus), and one within-subject
factor of Conditioning Day (at four levels: conditioning days 1 to 4). Conditioned gaping
responses and aversion-related behaviours (excluding gaping) from the drug-free test day
were analyzed using separate, 2 x 2 ANOVAs. The between-subjects factors were Drug
(at two levels: 96 mg/kg LiCl and 0.9% NaCl) and Estrous Cycle Phase (at two levels:
proestrus and diestrus). As this study was exploratory, Fisher’s least significant
difference (LSD) test was used for post hoc pairwise comparisons. All statistical tests
used α=0.05 as a significance criterion. Statistical analyses were performed using IBM
SPSS Statistics 23 for Windows.

3.3 Results
3.3.1 Conditioning days
The frequency of gaping and aversion-related behaviour during the four conditioning
days were analyzed in order to evaluate the differences in acquisition rate of conditioned
disgust responses among the experimental groups.

3.3.1.1

Conditioned gaping behaviour

The 2 x 2 x 4 mixed design ANOVA revealed a significant effect of Conditioning Day (1
to 4), F(3, 81) = 5.85, p < .01, and a significant main effect of Drug (NaCl or LiCl), F(1,
27) = 21.89, p < .001. A significant Conditioning Day x Drug interaction was also found,
F(3, 81) = 5.85, p < .01. As shown in Figure 3.5, both LiCl groups showed significantly
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Conditioned Gaping
Behaviour on Conditioning Days

16

Proestrus LiCl (n=8)
Diestrus LiCl (n=7)
Proestrus NaCl (n=8)
Diestrus NaCl (n=8)

14

Response Frequency

12
10
8
6
4
2
0
1

2

3
Conditioning Day

4

Figure 3.5. Conditioned Gaping Behaviour on Conditioning Days. Mean (± sem)
frequency of conditioned gaping responses expressed by the 4 groups (Proestrus+LiCl,
Diestrus+LiCl, Proestrus+NaCl, & Diestrus+NaCl), during the 30-minute conditioning in
the distinctive context across four conditioning days (96h apart). Both LiCl groups
showed significantly more gaping behaviour than both NaCl groups (p < .001). Both
Proestrus+LiCl and Diestrus+LiCl showed increased gaping behaviour across
conditioning days (p < .01), while Proestrus+NaCl and Diestrus+NaCl did not.
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higher gaping responses than NaCl groups. Furthermore, there was a monotonic increase
in gaping frequency for both Proestrus+LiCl and Diestrus+LiCl groups over the four
conditioning days.

3.3.1.2

Conditioned aversion related behaviour

Conditioned aversion-related behaviours not including gaping (forelimb flails, paw
treads, and chin rubs) were analyzed as a composite score. The 2 x 2 x 4 mixed design
ANOVA revealed a significant main effect of Drug, F(1, 27) = 5.88, p < .05. As shown in
Figure 3.6, both LiCl groups showed significantly more conditioned aversion-related
behaviours than NaCl groups. No other significant main effects or interactions were
found.

3.3.2

Drug-free test day
3.3.2.1

Conditioned gaping behaviour

The 2 x 2 between-subjects ANOVA revealed a significant main effect of Drug, F(1,27)
= 23.48, p < .001. A significant main effect of Phase, F(1,27) = 11.50, p < .01, as well as
a significant Drug x Phase interaction, F(1,27) = 11.50, p < .01 were found. As shown in
Figure 3.7, post-hoc pair-wise comparisons (Fisher’s LSD) for phase differences revealed
that rats in Group Proestrus+LiCl displayed significantly higher frequencies of
conditioned gaping responses, relative to Diestrus+LiCl, Proestrus+NaCl, and
Diestrus+NaCl groups (p < .001).

3.3.2.2

Conditioned aversion related behaviour

Conditioned aversion-related behaviours not including gaping (forelimb flails, paw
treads, and chin rubs) were analyzed as a composite score. The 2 x 2 between-subjects
ANOVA revealed a significant main effect of Drug, F(1, 27) = 19.82, p < .001, and
significant main effect of Phase F(1, 27) = 4.50, p < .05. No significant interaction was
found. As demonstrated in Figure 3.8, post hoc analyses (Fisher’s LSD) for phase
differences revealed that rats in Group Proestrus+LiCl displayed significantly higher
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Conditioned Aversion Related Behaviours (Excluding Gaping)
on Conditioning Days
Proestrus LiCl (n=8)
Diestrus LiCl (n=7)
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Figure 3.6. Conditioned Aversion Related Behaviours on Conditioning Days. Mean
(± sem) frequency of conditioned aversion related behaviours expressed by the 4 groups
(Proestrus+LiCl, Diestrus+LiCl, Proestrus+NaCl, & Diestrus+NaCl), during the 30minute conditioning in the distinctive context across four conditioning days (96h apart).
Both LiCl groups demonstrated significantly more aversion related behaviours than both
NaCl groups (p < .05). No significant conditioning day effects were seen.
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Figure 3.7. Conditioned Gaping Behaviour on Test Day. Group mean (+ sem)
frequency of total gaping responses expressed by groups LiCl+Proestrus, LiCl+Diestrus,
NaCl+Proestrus, and NaCl+Diestrus during the 10 min test in the distinctive context in
the absence of drug treatment (n= 7-8/experimental group). LiCl treated animals showed
significantly more gaping than NaCl treated animals ***(p < .001), and LiCl+Proestrus
showed significantly more gaping than LiCl+Diestrus ***(p < .001).
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Figure 3.8. Conditioned Aversion Related Behaviour on Test Day. Group mean (+
sem) frequency of total aversion related responses (excluding gaping) expressed by
groups LiCl+Proestrus, LiCl+Diestrus, NaCl+Proestrus, and NaCl+Diestrus during the
10 min test in the distinctive context in the absence of drug treatment (n= 7-8/
experimental group). LiCl treated animals showed significantly more aversion related
behaviour than NaCl treated animals ***(p < .001), and LiCl+Proestrus showed
significantly more aversion related behaviour than LiCl+Diestrus *(p < .05).
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frequencies of conditioned aversion-related behaviours than Diestrus+LiCl (p < .05),
Proestrus+NaCl (p < .001), and Diestrus+NaCl groups (p < .001).

3.3.3 Estrous cycle determination
Following coding of the lavage samples under 10x magnification under the microscope, it
was confirmed that each rat assigned to the diestrus or proestrus group was in fact
conditioned and tested during diestrus or proestrus, respectively. No disruptions to
estrous cycle phases were observed in the rats following drug treatment.

3.4 Discussion
The current study investigated the relationship of the estrous cycle with the formation of
conditioned disgust behaviours in the rodent model of AN, using 96 mg/kg of nauseainducing LiCl and a saline control. It was hypothesized that proestrus rats would show
greater levels of conditioned disgust responses relative to diestrus rats and this hypothesis
was supported. Results showed that on the drug free test day, rats conditioned and tested
during proestrus demonstrated greater levels of conditioned gaping and other aversionrelated behaviours (i.e., forelimb flails paw treads, and chin rubs) relative to rats
conditioned and tested during diestrus. This finding is consistent with previously
observed effects of estrogens on other conditioning paradigms (Farr, Banks, & Morley,
2000; Lin et al., 2015; Ossenkopp et al., 1996).
Although increased levels of estrogens were associated with increased conditioned
disgust responses on test day, no such effects were seen on the conditioning days. That is,
proestrus and diestrus rats learned the conditioned disgust behaviours at the same rate.
During the conditioning trials, rats were injected with LiCl and immediately placed into
the distinctive context. This allowed the association between feelings of nausea and the
distinctive context to form, which then manifested as conditioned gaping. When the rats
were placed into the distinctive context drug-free on test day, the presence of conditioned
gaping behaviour indexed this learned association. In the current study, estrous cycle
phase effects were only seen on drug-free test day. This suggests that estrogen enhances
the memory component of the AN model, rather than augmenting learning during
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conditioning trials. This inference is supported by numerous studies that have
demonstrated estradiol’s beneficial effects on hippocampal-dependent spatial memory
(Al Abed et al., 2016; Barker & Galea, 2010; Frye, Duffy, & Walf, 2007; Sandstrom &
Williams, 2004; Tuscher, Fortress, Kim & Frick, 2015). Estradiol likely exerts its effect
on memory by increasing dendritic spine density on CA1 pyramidal neurons, as well as
increasing proliferation of new neurons in the hippocampus. These effects of estradiol on
the hippocampus were first discovered by Woolley and McEwen (1993) and have since
been replicated by numerous labs (Barha, Dalton & Galea, 2010; Frankfurt & Luine,
2015: Frick et al., 2004). 17β-estradiol specifically dose-dependently upregulates cell
proliferation in the dentate gyrus of adult female rats (Barha et al., 2009). Both ER-α and
ER- β have been shown to be involved in estradiol-increased cell proliferation in the
dentate gyrus of adult female rats (Mazzucco et al., 2006). With regards to non-spatial
working memory, the effects of estradiol are more complex. Studies have shown that
injections of low-dose estradiol facilitates non-spatial working memory, while high-dose
estradiol impairs it (Barha et al., 2010; Wide, Hanratty, Ting, & Galea, 2004). The effects
of estrogens on the brain are both region and memory task specific. Estrogens seem to
facilitate hippocampal-dependent learning, but attenuate striatal-dependent learning
(Davis, Jacobson, Aliakbari, & Mizumori, 2005). This is reiterated in the study by Fader,
Johnson, and Dohanich (199), that demonstrated that estrogen improves spatial working
memory, but not reference memory. Thus, though the enhancing effects of estrogen on
hippocampal-dependent memory specifically are well documented (Joesselyn et al.,
2015; Rosenbaum et al., 2001; Winocur et al., 2013), estrogen’s effects on other types of
memory are less clear.
The present study demonstrated a positive relationship between estrogen levels and
presumed memory for learned disgust, but perhaps this result would be better explained
by the increase in nausea/disgust itself during conditioned trials. As demonstrated in
Figure 3.5, Proestrus+LiCl rats do have a higher gaping response frequency than
Diestrus+LiCl rats, albeit this was not significant. It is possible that with a larger sample
size and thus more power, a significant effect would emerge. In this case, estrogens
would be implicated not only in the memory of the association between the context and
disgust, but also in the acquisition of this association. This explanation is plausible as
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there is substantial research connecting estrogens to nausea and malaise in general, such
as estradiol-related increases in nausea during pregnancy (with contributions from
progesterone as well), or in women taking oral contraceptives (Ganesan, 1994; Lagiou et
al., 2003; Matchock, Levine, Gianaros, & Stern, 2008). Since estrogens have been linked
to nausea in other studies, it is possible that in the current study, the increased levels of
estrogen in proestrus rats is causing greater disgust-related behaviours during
conditioning days. Future studies should examine this possibility by using larger sample
sizes.
Past studies measuring exact hormone levels in rats have shown that during proestrus,
estradiol levels in serum are approximately 90 pg/mL, while during diestrus estradiol
levels are about 30 pg/mL (Faccio et al., 2013). This represents a marked difference in
estradiol levels between the two phases. Progesterone levels in serum however, average
at about 35 ng/mL during proestrus, and 20 ng/mL during diestrus (Faccio et al., 2013).
Although the present study did not measure hormone levels in the rats, this evidence
suggests that the change in behaviour seen in proestrus rats is likely due to the large
difference in estradiol levels compared to diestrus rats. The difference in progesterone
levels from proestrus to diestrus is not as pronounced, and likely not causing the
increased AN behaviours seen in proestrus rats.
Tracking the estrous cycle is a clever way of using female rats’ natural ebb and flow of
hormones to examine the putative effects of hormones on certain behaviours. This
method has the advantage of being relatively non-invasive and doesn’t put the animal
through the stress of a surgery. The caveat is, however, that the phases of the estrous
cycle are a relative measure of estrogen and progesterone, and do not provide an exact
measure of the hormones. Thus, although it is likely estrogens causing the increased AN,
the present study does not definitively prove this. The current methodology was used due
to the exploratory nature of the study. Now that additional support has been provided for
estrogen’s role in AN, a follow up study should explore this further by means of
ovariectomy and estrogen and/or progesterone replacement.
AN is not the only syndrome in which women exhibit higher incidences of nausea than
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men. In a study identifying risk factors for post-operative nausea and vomiting (PONV),
female sex was identified as the strongest patient-related predictor (Fujii, 2009; Gan,
2006). Female sex is also a known risk factor for motion sickness susceptibility (Paillard
et al., 2013), which is highly relevant to the current study given that provocative
vestibular stimulation has been used as the unconditioned stimulus in similar conditioned
disgust paradigms (Cordick, Parker, & Ossenkopp, 1999; Limebeer et al., 2008;
Ossenkopp et al., 2003). Moreover, motion sickness has been shown to fluctuate
throughout the menstrual cycle, in accordance with fluctuating estrogen levels (Golding,
Kadzere, & Gresty, 2005).
Most studies employing animal models of AN have used male rats, with some recent
studies examining putative sex differences (Cloutier et al., 2017). The existence of sex
differences in multiple types of nausea highlights the importance of the use of female
rats, and taking the estrous cycle into account, in the animal model for AN. In addition to
context, taste cue is another stimulus that can elicit a conditioned disgust response when
paired with a toxin. Taste aversion/avoidance paradigms, where rats are injected with a
salient taste cue combined with a LiCl to induce nausea, produce a similar conditioned
disgust effect to context-conditioning (Parker et al., 2006; Cloutier, Cross-Mellor,
Kavaliers, & Ossenkopp, 2011). The effect of the estrous cycle has yet to be explored in
taste aversion/avoidance paradigms. Future studies should examine a putative role of
estrogen in the development of conditioned taste aversion/avoidance.
Developing a comprehensive understanding of AN and its relation to the estrous cycle
will provide a strong foundation for which treatment and prevention efforts can be
directed. At present, the best-known strategy to defend against AN is to prevent it from
developing in the first place, by controlling acute and delayed CINV immediately using
5-hydroxytryptamine3 (5-HT3) and neurokinin1 receptor (NK1) antagonists. These
medications are well-documented to alleviate vomiting, but their effects on nausea are
more complicated (Miner & Sanger, 1986; Costall, Domeney, Naylor, & Tattersall, 1986;
Sanger & Andrews, 2006). And further, once it does develop, AN is refractory to antiemetic medication for the most part. This study lends support to the hypothesis that
estrogen augments the learning of this conditioned nausea. If this idea is further
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supported, it is possible estrogen antagonism could become a new avenue to explore in
terms of pharmacological treatment options. Additionally, women may be able to prevent
the severity of AN by adjusting their chemotherapy schedule around their menstrual
cycle, such that the treatments never coincide with the days where estrogen levels are the
highest. Due to the clinical relevance of AN, further human studies are necessary in order
to explore this phenomenon.

3.4.1 Conclusions
It was hypothesized that proestrus rats would condition higher levels of disgust responses
relative to diestrus rats in the rodent model of AN. It was found that proestrus rats
exhibited significantly stronger conditioned disgust responding via gaping and other
aversion-related behaviours (i.e., chin rubs, paw treads, and forelimb flails), when reexposed to a distinctive context previously paired with the toxin, LiCl. This estrous cycle
phase effect was not seen during conditioning days, which suggests estrogens may be
impacting memory for the conditioned association, rather than the learning process itself.
The present findings provide support that estrogens may contribute to the higher
incidence of AN in females, a finding which should be further examined.
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Chapter 4
4

General Discussion

Cancer patients list chemotherapy-induced nausea and vomiting (CINV) as one of the
most distressing and bothersome events that negatively affects quality of life. While both
sexes do experience this distressing side-effect, evidence suggests that there is a sex
difference in the prevalence and severity of CINV, where females have been shown to be
more susceptible relative to males (Molassiotis, Stamataki, & Kontopantelis, 2013;
Sekine, Segawa, Kubota, & Saeki, 2013; Warr, 2014;). This sex difference is seen in all
phases of CINV, which includes acute, delayed, and anticipatory. In the animal model of
anticipatory nausea (AN), which was developed to study the anticipatory phase of CINV,
a sex difference in favour of females has also been seen (Cloutier, Kavaliers, &
Ossenkopp, 2017). Although this sex difference is well established, the reason behind the
increase in CINV seen in females remains unknown. The current thesis explored the
mechanism behind the known sex difference in CINV using two diverse approaches.
In Chapter 2, sex differences in the development of anticipatory, acute, and delayed
CINV in pediatric oncology patients were examined. Patients were split into three groups
based on pubertal status: pre-, mid-, and post-pubertal. It was hypothesized that sex
differences in the development of CINV would only be seen in the post-pubertal age
group, due to the higher levels of estrogen in this group of females. This post-pubertal
sex difference was in fact observed in delayed CINV. Notably, in both the pre-, and midpubertal patients, no sex differences were seen in acute or delayed CINV control. This
agrees with multiple studies which found that female sex is not a significant predictor of
CINV in pediatric oncology patients (Aseeri, Mukhtar, Khansa, Elimam, Jastaniah, 2013;
Dupuis et al., 2017; Holdsworth, Raisch & Frost, 2006; Vol et al., 2016). As previously
established, female sex is a risk factor for the development of CINV in the adult oncology
population. The present study demonstrated that the observed sex difference in CINV
may in fact emerge around adolescence, which indicates the involvement of sex steroids.
In terms of anticipatory CINV, no significant sex differences were seen in the pre-, mid-,
or post-pubertal groups. However, although this difference was not significant, post-
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pubertal females did show substantially higher proportions of anticipatory CINV than
males. Since uncontrolled acute or delayed CINV is a risk factor for the development of
anticipatory CINV (Lohr, 2008), and post-pubertal females did demonstrate significantly
less delayed CINV control than males, it is possible that this post-pubertal sex difference
in anticipatory CINV would prove to be significant with a larger sample size.
In order to further investigate estrogen’s effects, in Chapter 3, the rodent model of
anticipatory nausea (AN) was employed to test whether the estrous cycle influences the
ability of female rats to form associations between a distinct context and feelings of
disgust (i.e., AN). The estrous cycle is the reproductive cycle of the female rat, and
consists of a cyclical rise and fall of estrogen and progesterone. The effects of estrogens
on various behaviours can be determined by tracking the rats’ estrous cycle, and
quantifying behaviours on specific days of the cycle. As predicted, on the drug free test
day, rats conditioned and tested during proestrus (high estrogen levels) demonstrated
greater levels of aversion-related disgust behaviour relative to rats conditioned and tested
during diestrus (low estrogen levels). And further, this effect was not seen on
conditioning days, suggesting estrogen is acting on the memory component of
conditioned disgust, rather than on the learning of the toxin-induced nausea itself. To the
best of our knowledge, this was the first study to demonstrate a significant estrous cycle
difference in conditioned disgust using the rodent model of AN. The results of this study
strengthen the notion that estrogens are involved in nausea in general, and also suggest
estrogens plays a role in CINV. This implies that females’ greater likelihood to
experience CINV may be in part due to their higher levels of circulating estrogens, in
comparison to males.
Taken together with the findings of Chapter 2, a strong indication for the involvement of
gonadal hormones has been established. The results of this thesis imply that estrogens
affect the development of CINV in the delayed phase, through increasing nausea itself,
and in the anticipatory phase, through increasing both nausea, and memory of the
conditioned nausea.
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One caveat of this thesis is that it does not definitively prove that estrogen is in fact the
gonadal hormone contributing to the effects shown. It may be possible that another
prominent female hormone, progesterone, is having an effect. While this possibility
cannot be eliminated without conducting a study involving direct hormone manipulation,
a number of findings in the literature suggest that progesterone has either minimal or
unpredictable effects on learning and memory or nausea. In a study examining the effects
of estradiol and progesterone on the acquisition of conditioned taste aversion (CTA), it
was found that estradiol, but not progesterone affected the acquisition of CTA learning.
In fact, some studies have shown that progesterone actually impairs performance of
spatial and working memory, and avoidance tasks in female rats (Braden et al., 2015; Fry
& Sturgis, 1995; Johansson et al., 2002). There is also evidence that women taking
progesterone as part of hormone therapy for menopause have an increased risk of
dementia as well as other cognitive impairments (Coker et al., 2010; Shumaker et al.,
2003). With regards to nausea, the research on progesterone’s connection has yielded
mixed results. In some studies, progesterone has been shown to have minimal
connections with the its development. In a study assessing pregnancy hormone levels in
relation to nausea, it was found that estradiol was positively associated with nausea with
or without vomiting, while no evidence was found for progesterone’s connection to
nausea during pregnancy (Lagiou et al., 2003). Conversely, there has been some research
which has shown that the elevation of the combination of progesterone and estrogen are
associated with the gastric dysrhythmias that correlate to pregnancy-related nausea
(Walsh, Hasler, Nugent, & Owyang, 1996). In a literature review on Hyperemesis
Gravidarum (HG), a condition which causes severe nausea and vomiting in early
pregnancy, it was concluded that progesterone’s connection to this condition is weak to
inconclusive, while estrogens are likely causally related to HG (Verberg, Gillott, AlFardan, & Grudzinskas, 2005).
These studies strongly suggest that elevated progesterone is not the reason for the
increase in CINV in females in comparison to males. While estrogen’s involvement
cannot be definitively proven without performing hormone manipulation experiments,
much of the literature points to it being a key contributing factor. Estrogen can increase
the number of dopamine receptors in the brain, while certain antiemetic drugs such as
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droperidol are designed to inhibit these dopamine receptors (Hruska & Sibergeld, 1980;
Tornetta, 1977). This suggests that estrogen may influence nausea through a dopaminemediated pathway. It has also been postulated that estrogen sensitizes vomiting centers
such as the area postrema and triggers nausea. The area postrema is a circumventricular
medullary structure implicated in the detection of toxins, such as LiCl, and acts as a
vomit-inducing center. Following exogenous administration of estradiol benzoate,
markers for neuronal activity are activated in the area postrema. In addition, area
postrema lesions eliminate the hypophagia expressed by male rats exposed to chronic
estradiol treatment (Bernstein, Courtney, & Braget, 1986). An intact area postrema is
critical for taste avoidance and aversion learning with LiCl (Eckel and Ossenkopp, 1996;
Ossenkopp & Eckel, 1994;1995). Estrogen can also act as the unconditioned stimulus in a
CTA learning paradigm (Hintiryan, Foster, Chambers, 2009; Ossenkopp et al., 1996), and
it can enhance LiCl-induced CTA (Ganesan & Simpkins, 1991).
While further research is required to determine estrogen’s specific involvement in CINV,
there is no shortage of research on the connection between estrogens and nausea and
vomiting in general. The results of the present thesis, along with the number of studies
that have drawn connections between estrogens and nausea, point to estrogens being a
key contributor to the sex difference seen in CINV in cancer patients.

4.1 Conclusions
In the present thesis, the possible mechanism behind the sex difference seen in CINV was
explored. This was done using two diverse approaches: a post hoc data analysis of CINV
in a pediatric oncology patient population, and a rodent model of AN to examine the
influence of the estrous cycle on the establishment of context-based disgust conditioning.
The human post hoc analysis revealed female pediatric patients demonstrate less delayed
CINV control than male patients, specifically in the post-pubertal age group. Both preand mid-pubertal patients did not show a sex difference in either anticipatory, acute, or
delayed CINV. The rodent study showed that rats conditioned and tested during a period
of high estrogen circulation (i.e., proestrus) demonstrate increased conditioned-disgust
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behaviours relative to rats conditioned and tested during a period of low estrogen
circulation (i.e., diestrus).
Future studies might extend these animal results by examining AN in rats in varying
pubertal stages, in both females and males. Given the results from the human study which
suggest a sex difference only appears once patients reach puberty, studying this theory in
rodents would further strengthen the animal model of AN as a useful preclinical tool.
Furthermore, the effects of ovariectomy and replacement of estrogen and/or progesterone
should be evaluated in female rats, as this would provide a clearer indication of which
gonadal hormone causes increased conditioned nausea-related behaviour. Future clinical
studies should examine this research question with a focus on puberty so that cliniciandefined pubertal status determination is part of the study’s methodology, as well as with
larger and more evenly divided sample sizes.
Until the mechanism behind the sex difference in CINV is completely understood,
treatment of and prophylaxis for CINV will be suboptimal, and will continue to have a
profound impact on cancer patients’ lives. The current thesis provides substantial support
to suggest that increased levels of estrogens in female patients may be the underlying
cause for the observed sex difference. These results provide a basis for future studies to
explore both direct hormone manipulation in the animal model, and hormone assays in
the clinical population, in order to further elucidate estrogen’s possible effects.
Uncovering this mechanism will ultimately help to alleviate the burden of CINV on
cancer patients, and the present thesis lays the groundwork that future studies can build
on.
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